.svg){kind=small}
Apr-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Stigma Grow has shown consistent performance in the Alberta market, particularly within the Capsules category where it maintained a solid third-place ranking from January to April 2025. This stability is noteworthy, considering the fluctuations often observed in the cannabis industry. In the Concentrates category, however, Stigma Grow experienced a slight decline, moving from 12th place in January to 14th place by April. This suggests a need for strategic adjustments to regain momentum within this segment. The brand's consistent sales numbers in Capsules, despite a dip in February, indicate a loyal customer base, but the downward trend in Concentrates could be a cause for concern if it continues.
In British Columbia, Stigma Grow's performance in the Capsules category displayed some variability, with rankings shifting from 7th to 8th place by April. This fluctuation might reflect competitive pressures or changing consumer preferences. The Concentrates category saw a relatively stable performance, holding steady at 15th place from March through April. Meanwhile, in Ontario, the brand maintained a consistent presence in the top 10 for Capsules, though it experienced a slight drop from 8th to 9th place by April. The absence of a top 30 ranking in Concentrates until March, when it reached 43rd place, could indicate a significant opportunity for growth or a need for increased focus in this area.
Competitive Landscape
In the Alberta cannabis capsules market, Stigma Grow has consistently maintained its position at rank 3 from January to April 2025, showcasing stability in a competitive landscape. While Tweed and Glacial Gold have dominated the top two positions, Stigma Grow's consistent ranking indicates a strong foothold despite the competitive pressure. Notably, Indiva has shown an upward trend, moving from rank 7 in January to rank 4 in April, which could pose a future challenge to Stigma Grow if this trajectory continues. Meanwhile, Frank has fluctuated slightly but remains behind Stigma Grow, indicating that while Stigma Grow's sales have seen some fluctuations, its market position remains relatively secure for now. This analysis suggests that while Stigma Grow is holding steady, it should monitor the rising performance of Indiva to maintain its competitive edge.
Notable Products
In April 2025, the top-performing product from Stigma Grow was Indica RSO Capsules 25-Pack (250mg) in the Capsules category, maintaining its consistent first-place ranking since January with sales of 4680. Phoenix Tears RSO (1g) held steady in second place in the Concentrates category, also retaining its rank from previous months. CBD Softgels 15-Pack (750mg CBD) continued to rank third in the Capsules category, although its sales have shown a notable decline compared to March. Phoenix Tears Resin (1g) remained fourth in the Concentrates category, with relatively stable sales figures over the months. A new entry in April, Blackberry Gelato Live Resin Dab Syringe (1g), debuted in fifth place in the Concentrates category, indicating potential growth in popularity.
```Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
